We reviewed 2019’s top developments in Canadian life sciences IP and regulatory law in our highlights article. Below were our top 10 reads:
#1 Update on biosimilars in Canada – October 2019
#4 Canada releases final amendments to Patented Medicines Pricing Regulations; in force July 1, 2020
#6 Amended PMNOC Regulations: Second Anniversary Update
#7 Federal Court issues two interlocutory decisions in section 8 pregabalin case
#8 Orders of prohibition relating to polymorphic form patent for PRISTIQ upheld on appeal
#9 Federal Court of Appeal confirms obviousness finding in section 8 bortezomib action against Teva
Related Publications & Articles
-
Minister of Health announces new bilateral agreements with provinces for rare disease drugs
Canada’s first-ever National Strategy for Drugs for Rare Diseases includes up to $1.4 billion in funding for provinces and territories, to be negotiated through bilateral agreements.Read More -
Alexion awarded injunction against Amgen in SOLIRIS patent action; Court considers anticipation by incorporation by reference
The Federal Court has granted Alexion a declaration of infringement and an injunction preventing Amgen from manufacturing, using, and selling its proposed biosimilar eculizumab product, BEKEMV, in Can...Read More -
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More